PT1149090E - Nova forma cristalina do sal de potassio de (s)-omeprazole - Google Patents

Nova forma cristalina do sal de potassio de (s)-omeprazole

Info

Publication number
PT1149090E
PT1149090E PT00903058T PT00903058T PT1149090E PT 1149090 E PT1149090 E PT 1149090E PT 00903058 T PT00903058 T PT 00903058T PT 00903058 T PT00903058 T PT 00903058T PT 1149090 E PT1149090 E PT 1149090E
Authority
PT
Portugal
Prior art keywords
crystaline
omeprazole
new
salt form
potassium salt
Prior art date
Application number
PT00903058T
Other languages
English (en)
Inventor
Maths Nilsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1149090E publication Critical patent/PT1149090E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT00903058T 1999-01-28 2000-01-18 Nova forma cristalina do sal de potassio de (s)-omeprazole PT1149090E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9900274A SE9900274D0 (sv) 1999-01-28 1999-01-28 New compound

Publications (1)

Publication Number Publication Date
PT1149090E true PT1149090E (pt) 2003-07-31

Family

ID=20414267

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00903058T PT1149090E (pt) 1999-01-28 2000-01-18 Nova forma cristalina do sal de potassio de (s)-omeprazole

Country Status (40)

Country Link
US (1) US6511996B1 (pt)
EP (1) EP1149090B1 (pt)
JP (1) JP2002535401A (pt)
KR (1) KR100624054B1 (pt)
CN (1) CN1231477C (pt)
AR (1) AR022425A1 (pt)
AT (1) ATE236899T1 (pt)
AU (1) AU768676B2 (pt)
BG (1) BG65060B1 (pt)
BR (1) BR0007647A (pt)
CA (1) CA2357744C (pt)
CZ (1) CZ300504B6 (pt)
DE (1) DE60002042T2 (pt)
DK (1) DK1149090T3 (pt)
DZ (1) DZ3001A1 (pt)
EE (1) EE04240B1 (pt)
EG (1) EG23980A (pt)
ES (1) ES2193937T3 (pt)
HK (1) HK1041259B (pt)
HU (1) HU226766B1 (pt)
ID (1) ID30095A (pt)
IL (1) IL144107A0 (pt)
IS (1) IS2019B (pt)
MY (1) MY119095A (pt)
NO (1) NO319719B1 (pt)
NZ (1) NZ512804A (pt)
PL (1) PL197881B1 (pt)
PT (1) PT1149090E (pt)
RS (1) RS50200B (pt)
RU (1) RU2237666C2 (pt)
SA (1) SA00200895B1 (pt)
SE (1) SE9900274D0 (pt)
SI (1) SI1149090T1 (pt)
SK (1) SK285626B6 (pt)
TN (1) TNSN00017A1 (pt)
TR (1) TR200102138T2 (pt)
TW (1) TWI269795B (pt)
UA (1) UA71594C2 (pt)
WO (1) WO2000044744A1 (pt)
ZA (1) ZA200105526B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
CN1842525A (zh) 2003-05-05 2006-10-04 兰贝克赛实验室有限公司 苯并咪唑衍生物的钡盐
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2007532677A (ja) * 2004-04-16 2007-11-15 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤、および運動促進薬の組み合わせ
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
NZ551970A (en) * 2004-06-24 2010-01-29 Astrazeneca Ab New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
WO2006073779A1 (en) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
CN100384839C (zh) * 2006-02-17 2008-04-30 中国科学院上海有机化学研究所 [(取代的吡啶基)甲基]亚磺酰基-1h-苯并咪唑类化合物及其对映体的锌盐的制备方法
WO2007148213A2 (en) * 2006-06-21 2007-12-27 Glenmark Pharmaceuticals Limited Novel polymorph of esomeprazole potassium and process for its preparation
GB2444593B (en) 2006-10-05 2010-06-09 Santarus Inc Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
US7906678B2 (en) 2006-12-04 2011-03-15 Bayer Schering Pharma Aktiengesellschaft Crystalline potassium salt of lipoxin A4 analogs
FR2920428B1 (fr) * 2007-08-29 2012-06-15 Univ Rouen Procede de dedoublement de sels de l'omeprazole
WO2009074997A2 (en) * 2007-12-10 2009-06-18 Lee Pharma Ltd. A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
CN102884178B (zh) 2009-12-08 2014-12-03 科德克希思公司 拉唑化合物的合成
CN102319223B (zh) * 2011-09-21 2013-06-19 石药集团欧意药业有限公司 一种埃索美拉唑冻干制剂及其制备方法
CN102633776B (zh) * 2012-03-28 2014-06-18 中山市仁合药业有限公司 一种埃索美拉唑及其钠盐的制备方法
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
UA41946C2 (uk) 1994-07-08 2001-10-15 Астра Актієболаг Оральна фармацевтична складова одинична дозована форма у вигляді таблетки, спосіб її одержання, упаковка у вигляді блістера та спосіб інгібування секреції шлункової кислоти і/або лікування шлунково-кишкових запальних захворювань
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
GB9423970D0 (en) 1994-11-28 1995-01-11 Astra Ab Oxidation
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B

Also Published As

Publication number Publication date
AU768676B2 (en) 2003-12-18
PL197881B1 (pl) 2008-05-30
IS2019B (is) 2005-06-15
EP1149090B1 (en) 2003-04-09
SK10372001A3 (sk) 2002-02-05
BG65060B1 (bg) 2007-01-31
EG23980A (en) 2008-02-27
DE60002042D1 (de) 2003-05-15
HUP0105313A2 (hu) 2002-05-29
CA2357744A1 (en) 2000-08-03
RS50200B (sr) 2009-07-15
CZ20012730A3 (cs) 2002-02-13
TNSN00017A1 (fr) 2005-11-10
DZ3001A1 (fr) 2004-03-27
NO20013665D0 (no) 2001-07-26
HK1041259A1 (en) 2002-07-05
JP2002535401A (ja) 2002-10-22
CN1339034A (zh) 2002-03-06
SE9900274D0 (sv) 1999-01-28
ZA200105526B (en) 2002-10-04
AR022425A1 (es) 2002-09-04
MY119095A (en) 2005-03-31
KR100624054B1 (ko) 2006-09-18
IS5989A (is) 2001-07-05
BR0007647A (pt) 2001-10-16
HK1041259B (zh) 2003-10-24
SA00200895B1 (ar) 2006-11-11
TR200102138T2 (tr) 2001-12-21
RU2237666C2 (ru) 2004-10-10
BG105841A (en) 2002-04-30
ID30095A (id) 2001-11-01
ES2193937T3 (es) 2003-11-16
DK1149090T3 (da) 2003-06-30
CN1231477C (zh) 2005-12-14
HU226766B1 (en) 2009-09-28
DE60002042T2 (de) 2003-12-18
NO20013665L (no) 2001-07-26
WO2000044744A1 (en) 2000-08-03
CA2357744C (en) 2009-06-16
CZ300504B6 (cs) 2009-06-03
US6511996B1 (en) 2003-01-28
NZ512804A (en) 2003-07-25
KR20010101699A (ko) 2001-11-14
TWI269795B (en) 2007-01-01
EP1149090A1 (en) 2001-10-31
EE200100395A (et) 2002-10-15
IL144107A0 (en) 2002-05-23
EE04240B1 (et) 2004-02-16
SI1149090T1 (en) 2003-10-31
ATE236899T1 (de) 2003-04-15
NO319719B1 (no) 2005-09-05
AU2469400A (en) 2000-08-18
HUP0105313A3 (en) 2003-01-28
UA71594C2 (uk) 2004-12-15
SK285626B6 (sk) 2007-05-03
YU53801A (sh) 2004-07-15

Similar Documents

Publication Publication Date Title
PT1149090E (pt) Nova forma cristalina do sal de potassio de (s)-omeprazole
PT991641E (pt) Forma cristalina de sal sodico de omeprazol
EE200100336A (et) CTLA-4 vastased inimese monoklonaalsed antikehad
EE201200006A (et) CTLA-4 vastased inimese monoklonaalsed antikehad
ID16866A (id) Kompleks kompleks inklusi garam-garam aril-heterosiklik
DE69906461D1 (de) Wechselaufbausystem
PT1274407E (pt) Utilizacao de agonistas de ppar-gama em doencas induzidas por netrofilos
ID23303A (id) Proses pemurnian
GB9807464D0 (en) Purification of human acid µ-glucosidase
ID28966A (id) Metoda pemurnian trietanolamina
IL147891A0 (en) Topical use of anti-muscarnic agents
ID27522A (id) Fasilitas untuk bermain
HK1042560A1 (zh) 環球旅行鐘
DK1082575T3 (da) Vandfri krystaller
EE200000690A (et) Kahejuhtmeline mitmekiiruseline akulaadija
NO20010060D0 (no) Vannrensing
EP1086119A4 (en) PURIFICATION OF ANTIBODIES
HUP0101830A3 (en) Purification carboxaldehyde
IS6626A (is) Kristallskenndur meðferðarmiðill
GB0201545D0 (en) "Water purification system"
MA26840A1 (fr) Cristaux d'inhibiteur d'echangeur sodium-hydrogene de type 1
ATE232544T1 (de) Selektive inhibitoren des mmp-12
FR2774984B1 (fr) Purification du thiophene
TW402109U (en) Improved elastic structure of spectacle sides
ITMI980151A1 (it) Protein-disolfuro isomerasi come agenti terapeutici